allogeneic human mesenchymal stem cells (allo-hMSCs)

DRUG3 trials

Sponsors

Longeveron Inc., Ihsan M Salloum, MD, MPH, University of Miami

Conditions

Acute Ischemic StrokeAlcohol Use DisorderFrailtyMajor Depressive DisorderMesenchymal Stem CellsStroke, AcuteStroke, IschemicStroke/Brain Attack

Phase 1

AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery

CompletedNCT02065245

Longeveron Inc.Frailty

Start: 2014-03-03End: 2020-10-02Updated: 2021-07-14

Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.

CompletedNCT03265808

Ihsan M Salloum, MD, MPHAlcohol Use Disorder, Major Depressive Disorder

Start: 2018-03-18End: 2025-07-30Updated: 2026-01-09

Unknown Phase

Expanded Access Multi-Patient Experimental Treatment Involving Allogeneic Human Mesenchymal Stem Cells (hMSCs) in Subjects With Acute Ischemic Stroke (EXPAND)

University of MiamiAcute Ischemic Stroke, Mesenchymal Stem Cells, Stroke, Acute +2

Updated: 2026-04-13

Related Papers

The impact of cell-based therapy on female sexual dysfunction: a systematic review and meta-analysis.

2023-09-01

Clinical Study of Mesenchymal Stem/Stromal Cell Therapy for the Treatment of Frailty: A Proposed Experimental Design for Therapeutic and Mechanistic Investigation

The Journals of Gerontology Series A2021-10-283 citations

Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial

The Journals of Gerontology Series A2017-07-17154 citations